4.6 Article

Neuroprotective Effects of a PSD-95 Inhibitor in Neonatal Hypoxic-Ischemic Brain Injury

Journal

MOLECULAR NEUROBIOLOGY
Volume 53, Issue 9, Pages 5962-5970

Publisher

SPRINGER
DOI: 10.1007/s12035-015-9488-4

Keywords

Neonatal hypoxic-ischemic brain injury; PSD-95; In vivo; Neonatal stroke; Neuroprotection

Categories

Funding

  1. Heart and Stroke Foundation of Canada [G-13-0003069]
  2. Scottish Rite Charitable Foundation of Canada [12104]
  3. National Sciences and Engineering Research Council of Canada [NSERC-249962-09]
  4. China Scholarship Council Fellowships
  5. CIHR-CGS-M studentship
  6. Ontario Graduate Scholarships
  7. Heart and Stroke Foundation of Canada

Ask authors/readers for more resources

The postsynaptic density-95 inhibitor NA-1 uncouples NMDA glutamate receptors from downstream neurotoxic signaling pathways without affecting normal glutamate receptor function. NA-1 attenuates NMDA receptor-mediated neuronal cell death after stroke in multiple models and species. However, its efficacy in providing neuroprotection in models of neonatal hypoxic-ischemic brain injury has not yet been tested. In this study, a modified version of the Rice-Vannucci method for the induction of neonatal hypoxic-ischemic brain injury was performed on postnatal day 7 mouse pups. Animals received a single dose of NA-1 intraperitoneally either before or after right common carotid artery occlusion. All experiments were performed in a blinded manner. Infarct volumes were measured 1 and 7 days after the injury, while behavioral tests were conducted 1, 3, and 7 days after injury. Administration of NA-1 before right common carotid artery occlusion or immediately after ischemia significantly reduced infarct volume and improved neurobehavioral outcomes 1, 3, and 7 days post-injury. The neuroprotection and improvement in neurobehavioral outcomes conferred by NA-1 in this mouse neonatal hypoxic-ischemic injury model imply that NA-1 will be effective in reducing neonatal stroke damage and thus could potentially serve as a therapeutic drug for prevention or treatment of neonatal stroke.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available